Simpson Millar LLP Solicitors in Birmingham, Bristol, Cardiff, Gateshead, Leeds, London, Manchester & Wimbledon

New Mesothelioma Study – Asbestos related cancer
The Dartmouth Medical School’s study may provide a new hope for patients facing the asbestos related cancer mesothelioma. The school which is based in New Hampshire, USA completed studies based on past work performed with methylthioadenosine phosphorylase (MTAP). A missing enzyme linked to several types of cancers including lung cancer, pancreatic cancer, Leukemia, Lymphoma and mesothelioma, researchers found that MTAP may be linked to the development of malignant tumors in those who lack the enzyme.

The study lead by Dr. Martin Lubin and Adam Lubin, researchers from the university, utilised two powerful chemical agents to form a treatment which may destroy tumours whilst protecting healthy cells.

The first agent, thioguanine, is a highly toxic drug that can damage both cancerous and healthy cells, whilst the other drug, fluorouracil, protects healthy tissues from the first agent’s toxicity. Both of these drugs are already in clinical use but are administered in low doses due to the high potency of the medications.

Although in its early stages, the study demonstrates the possibility of attacking tumors that are resistant to these drugs, whilst still protecting healthy tissue. Dr. Lubin believes that successful animal studies will lead to clinical use as soon as possible.

The condition of malignant mesothelioma typically develops after exposure to asbestos. When toxic asbestos fibres are inhaled, they may become lodged in organs or body cavities, causing inflammation or infection. Many patients do not demonstrate symptoms of the cancer for 20 to 50 years after initial exposure occurred, allowing mesothelioma to progress to later stages of development. There is no cure for mesothelioma however treatment options are available such as radiation; chemotherapy and surgery are available to prolong the sufferers’ life.

If you have been diagnosed with mesothelioma and you believe you contracted this disease due to the negligence of a third party you could be entitled to compensation. Give our occupational disease and illness solicitors a call on 0800 634 1632 or send your query via email using our online form.

This article was written by Helen England, Solicitor, Occupational Illness Team.

Useful info:

Emma Costin
16/09/2009


Share |


Disclaimer: No information on this website shall be construed as legal advice and information is offered for general information purposes only based on the current law when the information was first displayed on this website. You should always seek advice from an appropriately qualified solicitor on any specific legal enquiry. Calls to or from our legal helpline may be recorded for training and monitoring purposes.

External links are provided for your convenience, but they are beyond the control of Simpson Millar LLP and no representation is made as to their content. Use or reliance on any external links and the content thereon provided is at your own risk. Full terms of use...


All copyright in this website and in any materials appearing on this website: © Simpson Millar 2008. Simpson Millar LLP solicitors is a limited liability partnership registered in England and Wales with registered number OC313936. Our registered office is: 27 St Paul's Street, Leeds LS1 2JG. Vat number: 235 9349 40.

Simpson Millar LLP has offices in Birmingham, Bristol, Cardiff, Gateshead, Leeds, London, Manchester and Wimbledon.

If you experience any problems when using this website please email: webmaster@simpsonmillar.co.uk.

Regulated by the Solicitors Regulation Authority: Registration No: 424940 Regulatory Information

Investors in People, Lexcel, Law Society Personal Injury, Family Law and Medical Negligence Panels Logo Images Law Society Personal Injury Panel Law Society Clinical Negligence Panel Law Society Family Law Panel Investors in People Lexcel Best Companies Guide - One to Watch